The US FDA’s Centre for Devices and Radiological Health. Credit: The US Food and Drug Administration / Flickr (Creative Commons).

Bioelectric medicine company Pulse Biosciences has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its CellFX system.

The clearance enables the indication of the system to be extended to include sebaceous hyperplasia treatment for patients with Fitzpatrick skin types I-III.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The approval was granted based on clinical data from the firm’s investigational device exemption (IDE)-approved trial for sebaceous hyperplasia treatment.

Recently, Pulse Biosciences secured 510(k) approval from the regulatory agency for two more treatment tips with larger spot sizes, specifically the 7.5mm and 10mm tip sizes, to treat larger benign lesions.

The company already offered tip sizes of 1.5mm, 2.5mm and 5.0mm for treatments.

The CellFX system is claimed to be the first commercial product to take advantage of the company’s Nano-Pulse Stimulation (NPS) technology for the treatment of several conditions.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

It is designed as a multi-application platform to offer a utilisation-based revenue approach for customers.

Pulse Biosciences president and CEO Kevin Danahy said: “We are pleased with the continued advancement of the CellFX System and its capabilities to enhance its value proposition for patients, clinicians and any potential commercial partner.

“These clearances provide further validation of the system’s strong safety and effectiveness profile.

“We would like to thank all of the investigators, the staff at their clinics and the patients who participated in these trials, as well as the FDA for their ongoing collaboration as we endeavour to offer the benefits of NPS technology to more patients.”

Providing nano-second pulses of electrical energy to non-thermally clear cells, the firm’s NPS technology avoids adjacent non-cellular tissue.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact